Clinical trial
Study of 2 Doses of Oral Live Attenuated Human Rotavirus (HRV) Vaccine for the…
NCT00134732 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00134732 |
|---|---|
| Title | Study of 2 Doses of Oral Live Attenuated Human Rotavirus (HRV) Vaccine for the Prophylaxis of Rotavirus Gastroenteritis |
| Official title | Assess the Immunogenicity, Safety & Reactogenicity of 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants (6-12 Weeks of Age at First Dose) Previously Uninfected With Human Rotavirus |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Infections, Rotavirus |
| Intervention type | Biological |
| Interventions | Live attenuated human rotavirus vaccine |
| Enrollment | 150 |
| Start date | Jul 1, 2005 |
| Completion | May 1, 2006 |
| First posted | Aug 25, 2005 |
| Last update posted | Sep 23, 2016 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: